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Watchful Waiting vs Immediate
Transurethral Resection for
Symptomatic Prostatism
The Importance of Patients' Preferences
Michael J. Barry, MD; Albert G. Mulley, Jr, MD, MPP; Floyd J. Fowler, PhD; John W. Wennberg, MD
The rate of resection for benign prostatic hypertrophy shows considerable
variability among small geographic areas. To help inform the decision to recom-
mend prostatectomy to men with prostatism without signs of chronic retention,
we performed a decision analysis to compare the expected outcomes with
immediate transurethral resection and watchful waiting. Data used in the model
originated from the medical literature, Medicare claims data, and patient inter-
view studies. In our base-case analysis for 70-year-old men, immediate surgery
resulted in the loss of 1.01 months of life expectancy, but when adjustments
were made for quality of life, immediate surgery was favored with a net utility
benefit of 2.94 quality-adjusted life-months. However, the analysis was particu-
larly sensitive to the degree of disutility attributed to the index symptoms of
prostatism. We conclude that patient preferences should be the dominant factor
in the decision whether to recommend prostatectomy.
(JAMA 1988;259:3010-3017)
WIDESPREAD variations in rates of
surgical procedures among geographi¬
cal areas have been interpreted as
evidence for professional uncertainty
concerning indications for these proce¬
dures.' Prostatectomy is one of the
more common procedures for which
such variation has been documented.2"6
Prostatectomy is performed both to
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prevent future morbidity and mortality
and to reduce symptoms. Review of the
literature and discussion with practic¬
ing urologists participating in the Maine
Medical Assessment Program indicate
little professional disagreement on the
need to operate on patients with chronic
urinary retention and large residual vol¬
umes or evidence of hydroureter or hy-
dronephrosis, which poses a threat of
urosepsis or renal failure. There is,
however, considerable disagreement
with the theory that prostatectomy ex¬
tends life expectancy among patients
without chronic retention by averting
potentially fatal complications of pros¬
tate disease or by avoiding the need for
surgery when the patient is older and at
higher operative risk. This controversy
has important implications for under¬
standing and dealing with geographic
variations in medical practice. If the
only function of prostatectomy were to
prevent outcomes such as urosepsis, re¬
nal failure, or death, which everyone
agrees are necessary to avoid, a single
"right" threshold for recommending
prostatectomy might be based on clini¬
cal or urodynamic predictors of these
complications. However, when the pri¬
mary purpose of prostatectomy is to re-
See also pp 3018 and 3027.
lieve symptoms and improve the quality
of life, the decision to operate should
depend heavily on the particular pa¬
tient's relative preferences for different
outcomes, including various levels of
urologie symptoms and potential opera¬
tive and nonoperative complications.
Indications for prostatectomy cannot,
therefore, be simply defined as appro¬
priate or not; a "right" rate for prosta¬
tectomy in a community cannot be
established without examining the indi¬
vidual decisions that contribute to the
rate. We developed a decision-analysis
model to understand more fully the pre¬
ventive and quality-of-life indications
for prostatectomy and to define the
most important probabilities and utili-
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Table 1.—Basic States in Markov Model
State Description
Spontaneous remission without
surgery
Remission after prostatectomy
Remission after prostatectomy except
for mild incontinence
Remission after prostatectomy except
for Impotence
Moderate symptomatic prostatism
Moderate urinary symptoms after
prostatectomy
Moderate urinary symptoms after
prostatectomy and mild Incontinence
Moderate urinary symptoms after
prostatectomy and impotence
Serious urinary tract Infection
Severe incontinence
Severe urinary symptoms after
prostatectomy
Severe urinary symptoms after
prostatectomy and mild Incontinence
Severe urinary symptoms afterprostatectomy and Impotence
Elective prostatectomy
Elective prostatectomy after Infection
Emergent prostatectomy after retention
Dead
»Because of the Markov assumption that transition
probabilities depend only on present state regardless
of previous states, the same symptom level must be
represented by more than one state (eg, ASX and
ASXpTUR), each of which has its own set of transition
probabilities.
fThe TURP state, with the same set of transition
probabilities, applies to Initial and repeated transurethral
prostatectomy. Separate TURP states, not shown, are
included in the model to reflect the assumption that
men rendered impotent or incontinent by an Initial
operation who then require reoperatlon will not be cured
of impotence or incontinence.
ties contributing to the decision wheth¬
er to recommend watchful waiting or
immediate transurethral prostatic re¬
section (TURP) for continent, sexually
active men with prostatism.
METHODS
The prostatectomy decision depends
on how the decision maker feels about
outcomes that may or may not occur in
the short term and during an extended
time period. Furthermore, the patient
may move from one health state to an¬
other repetitively over time. For exam¬
ple, symptoms may recur in the man
whose operation was initially success¬
ful. When clinical decisions depend on
transitions among health states during
an extended time period, Markov mod¬
els can be used to estimate prognosis in
patients treated with different strate-gies."0
We used a Markov model to estimate
the prognosis for continent, sexually ac¬
tive men with symptomatic prostatism
who undergo watchful waiting (the "fol¬
low" strategy) or immediate TURP(the "operate" strategy). Transurethral
prostatic resection was selected rather
than open prostatectomy because it is
the procedure performed most often in
the United States. Men with postvoid
residual volumes greater than 200 mL
or creatinine values greater than 180
Table 2.—Relative Utility Estimates (With Ranges for Sensitivity Analysis) in Quality-Adjusted Months
State*
"Base-Case"
Estimate
Sensitivity Analysis
Low Estimate High Estimate
ASXpTUR 1.00
ASX 0.97t .90
STABLESX, STABpTUR 0.89 .85 .97
ASXIMP, ASXWET 0.89 .50 .99
TURP, UTITURP 0.82 .50 .90
WORSpTUR 0.73 .40 .80
UTI, INCONT 0.50 .70
RETTURP 0.25 .50
DEAD 0.0
*See Table 1 for an explanation of the basic states in the Markov model.
tThe utility of the ASX state relative to ASXpTUR was discounted slightly by Woodward et al because of the
disutility of the apprehension of adverse events such as acute retention or infection or eventual surgery. In addition,
men who spontaneously improve are likely to be putting up with more minor symptoms than men improved after
prostatectomy.
tThe estimate by Woodward et al of 0.50 as the utility for urinary incontinence implies severe incontinence.
Because the Maine Prostatectomy Study indicates that lesser degrees of incontinence are more common and are
associated with decrements In mental health scores similar to those associated with postoperative impotence, we
have added WET and IMP states reflecting these two postoperative conditions that can be combined (assuming
Independence) with states reflecting degree of Irritative and obstructive symptoms (¡e, ASX, STAB, WORS). We
assumed that WET and IMP, states not addressed by Woodward and colleagues, have a utility equal to moderate
prostatism (STABLESX).
µ    /  (2 mg/dL), which may reflect
obstructive uropathy, as well as men
with evidence of prostate cancer, ady-
namic bladder, or other urologie disease
are not considered. Seventeen basic
states of prostatic health are incorpo¬
rated in the model (Table 1). Men in each
state may make transitions to other
states with each cycle of one month's
duration, a period that is sensitive to the
duration of morbidity that may occur in
some of the states (eg, serious urinary
tract infection [UTI] or TURP). Transi¬
tion probabilities were estimated from
three sources: the published medical lit¬
erature, the Medicare Part A Hospital
Claims database for New England,5 and
survey data from the Maine Medical As¬
sessment Program's Maine Prostatec¬
tomy Study.11
Time spent in each state is not of
equal value; quality adjustment is nec¬
essary based on the relative values of
the various states. A month in the
"asymptomatic after prostatectomy"(ASXpTUR) state was assigned a value
of 1.0 quality-adjusted month. A month
in the "dead" (DEAD) state is assigned
a value of 0.0. Utilities for other states
were modified from Woodward and col¬
leagues12 and appear in Table 2.
We elected to use a starting age of 70
years, the median age for surgery in the
Maine Prostatectomy Study, for a "base
case" to estimate expected utility for
each strategy. For purposes of the anal¬
ysis, we assumed the men making the
decision had "moderate" symptoms of
prostatism as defined by the symptom
index developed for the Maine Prosta¬
tectomy Study11; these men formed the
largest symptom group in that study.
Men can then make transitions to "mild"
symptoms (ASX, ASXpTUR) or "se¬
vere" symptoms (WORSpTUR) or re¬
main unchanged with moderate symp¬
toms (STABLESX, STABpTUR). It is
important to remember that these
states are defined by an objective scale
of symptom frequency; men in these
states, because of differing personal
utilities, might actually rate the same
symptom level anywhere from not both¬
ersome at all to intolerable. The model
was run for 30 years (360 cycles), by
which time more than 99.5% of all quali¬
ty-adjusted months were accumulated;
consideration of longer time frames did
not alter the difference in prognosis
between strategies.
Assumptions and Data
Several general assumptions were
made: (1) Men followed up carefully
without TURP will not develop irre¬
versible azotemia due to obstructive
uropathy, because those who develop
evidence of chronic obstruction will be
operated on. (2) All episodes of serious
UTI and urinary retention in the "fol¬
low" cohort are attributable to benign
prostatic hypertrophy, and the risks are
reduced by a constant percentage after
TURP. (3) Symptomatic outcomes of
TURP are no different with immediate
surgery or following a period of watch¬
ful waiting (ie, irreversible bladder de¬
compensation does not result in a symp¬
tomatic "loss to cure" when surgery is
delayed). (4) Transurethral prostatic
resection does not prevent mortality
from adenocarcinoma of the prostate.(5) Learning about incidental prostate
cancer found at TURP does not reduce
utility of subsequent life-months due to
cancer fear. (6) Men who undergo
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TURP with good results (transition to
ASXpTUR or even ASXIMP or ASX-
WET) will undergo TURP again if
symptoms deteriorate to the moderate
range; however, men who do not im¬
prove after TURP will require further
deterioration before submitting to reo-
peration, and men made much worse
/(WORSpTUR or INCONT) will not
submit to reoperation.
Transition Probabilities
Transition probabilities are the one-
month probabilities that individuals will
move from one state to another; all indi¬
viduals who do not make a transition to a
different state remain in the same state
for another cycle. When an incidence
density (D) is given in or calculated from
the medical literature (events per per¬
son time), a monthly probability is cal¬
culated using the equation: monthly
probability = l-eD, where D is in
events per person-month.13
Monthly transition probabilities are
summarized in Tables 3 and 4; the basis
for these estimates is described in the
Appendix.
Calculations were performed using
"SMLTREE," a decision-analysis pro¬
gram for the IBM microcomputer that
features an ability to incorporate
Markov processes.14
Future life-months were not dis¬
counted in the base case. However, in a
sensitivity analysis, we examined the
effects of different discount rates (d) by
dividing the utility of future life-months
by (1 + d)', where t is the elapsed time in
years from the starting age.16
RESULTS
Base Case:
The 70-Year-Old Man
In the base-case analysis, using prob¬
abilities appropriate for the 70-year-old
sexually active continent man with
"moderate" symptoms but without
chronic obstruction, the expected quali¬
ty-adjusted utility for the "follow"(watchful waiting) strategy is 119.97quality-adjusted life-months (QALMs).
The expected utility for the "operate"(immediate surgery) strategy is 122.91QALMs; surgery provides a net ex¬
pected benefit of 2.94 QALMs. While
the 70-year-old choosing surgery faces
an expected loss of 1.07 QALMs due to
operative risk, he would gain an ex¬
pected 0.06 QALMs due to prevention
of urosepsis and 3.95 QALMs due to
improvement in symptoms of pros¬
tatism.
When no quality adjustments are
made, the model predicts a net loss of
1.01 months of life expectancy for those
who undergo immediate operation.
Therefore, for patients without chronic
Table 3.—Summary of Transition Probabilities for One-Month Cycles of Markov Model*
STABLESX ASX TURP UTI UTITURP RETTURP
STABLESX 1-X .024 (1-12)
.0 (13-360)
.0049 .00033 .00033 + t
ASX .004 1- .00033 .00033
UTI .97
TURP(UTITURP, RETTURP) • 15§ 1- .055 .015 .005§
.03
STABpTURt ASXpTURj WORSpTUR UTI RETTURP INCONT
ASXpTUR(ASXIMP, ASXWET) .0018» 1- 
.00007
.00007
STABpTUR 1- (STABIMP, STABWET) .001811
.00007 .00007
WORSpTUR 1- (WORSIMP, WORSWET)
_
INCONT 1- 0 0
*See Table 1 for an explanation of the basic states In the Markov model.
t + indicates age-dependent death rates taken from gender-specific life tables for US population (see Appendix);
and + +, age-dependent operative mortality estimated from Medicare claims data (see Table 4).
tSymptom levels reflect irritative and obstructive symptoms with or without postoperative impotence or mild
incontinence (see Appendix).§Actually these probabilities are applied to survivors who do not undergo immediate reoperation; for example,
p(TURP—>STABpTUR) = 0.15(1 -pDEATH-pRETTURP). In addition, for each of these symptomatic transitions
men may develop minor Incontinence (.04) or Impotence (.05).(Patients who make this transition are assumed to go on to repeated TURP.
Table 4.—Operative Mortality as a Function of Age*
Predicted
Operative Mortality
Age, y 12 wk 6wk
65_.0097_.0038
70_.0155_.0065
75_.0240_.0113
B0_ 391_.0196
85 .0620
.0340
 Estimated from Medicare Part A Hospital Claimsdata for 16446 men who underwent transurethral
prostatectomy for benign disease in New England in
1983 through 1985, from a logistic regression model
and using the log odds of death during 12 or six weeksfollowing elective prostatectomy as the dependent var¬
iable and age as the independent variable.
obstruction, the decision to operate re¬quires a trade-off between expected
quality of life and quantity of life.
Because the man who is already impo¬
tent cannot lose utility due to postopera¬
tive sexual dysfunction, the net expect¬
ed benefit of the operate strategy will be
higher, ie, 3.50 QALMs. The man who
opts for watchful waiting may not per¬
manently forgo surgery. The model in¬
dicates that 42% of 70-year-old men who
initially defer surgery would eventually
undergo TURP for symptom deteriora¬
tion, acute retention, or serious UTI.
The model also indicates that the 70-
year-old man opting for early surgery
may face the same decision again; the
model predicts a cumulative probability
of 21% for at least one repeated opera¬
tion. Table 5 lists the cumulative proba¬
bility of initial TURP in the "follow"
strategy and of reoperation in the "oper¬
ate" strategy during the 30 years follow¬
ing the initial decision.
The time-dependence of the benefit of
Table 5.—Probability of Initial Operation in Follow'
and Reoperation in 'Operate' Over Time
"Operate"
"Follow" Probability
Elapsed Probability of Repeated
Time, y_ofTURP»_TURP
1 .05 .03
.21 .10
10_.33_·16_
20_.40_.Z\_
30 .42 .21
*TURP indicates elective prostatectomy.
surgery can be analyzed by examining
accrued quality-adjusted months at dif¬
ferent numbers of cycles. At one year,
the net benefit of "operate" is only 0.40
QALMs; at five years, 1.59 QALMs; and
at ten years, 2.40 QALMs.
Sensitivity Analyses
One-way sensitivity analyses for the
probabilities and utilities in the model
for the base-case starting age of 70
years are found in Tables 6 and 7. Inter¬
estingly, the analysis was insensitive to
variation in the assumptions regarding
the "preventive" nature ofTURP—that
is, the differential risk of retention and
infection between the two strategies.
To some degree, this finding reflects our
structural assumption that, although
the utility of an episode of retention or
infection was low, the surgical outcomes
following such an event were similar.
However, even ifwe doubled the proba¬
bility of a worse symptomatic outcome
in UTITURP and RETTURP, the net
benefit of surgery increased to only 2.98
QALMs. The analysis was also quite
insensitive to discount rate.
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Table 6.—One-Way Sensitivity Analyses—Probabilities
Variable Value
1. Probability of spontaneous remission(mo 1-12)
.000
.024t
.048
4.35
2.94
1.86
2. Probability of symptomatic deterioration
after spontaneous remission
.0
.004t
.008
2.38
2.94
3.28
3. Probability of UTI .00000
.00033t
.00100
2.95
2.94
2.93
4. Probability of death from UTI .00
.03f
.10
2.87
2.94
3.10
5. Relative risk ratio of acute retention and
UTI after TURP
1.00
0.20t
0.00
2.68
2.94
3.01
6. Probability of operative mortality (times
baseline)
0.5  
1.0xf
1.5x
2.0  
2.5  
3.0  
3.61
2.94
2.28
1.61
0.95
0.29
7. Probability of acute retention .000
.00033t
.0010
3.00
2.94
2.82
8. Relative risk of operative mortality after
retention
1-0t
2.0
3.0
2.94
2.98
3.03
9. Relative risk of operative mortality after
infection
1.0t
2.0
3.0
2.94
2.98
3.03
10. Probability of severe incontinence after
TURP
.000
.005t
.010
3.20
2.94
2.69
11. Probability of severe symptoms after
TURP
.01
.055t
.11
4.16
2.94
1.47
12. Probability of moderate symptoms after
TURP
.05
•
15t
.30
3.91
2.94
1.50
13. Probability of early reoperation .005
.015t
.030
2.96
2.94
2.92
14. Probability of late reoperation for
recurrence or stricture
.0
.0018t
.0040
2.85
2.94
3.08
15. Discount rate, % 0t
5
10
2.94
2.27
1.85
16. Probability of postoperative impotence .00
.05t
.10
3.50
2.94
2.42
17. Probability of postoperative mild
incontinence (wetness)
.00
.04t
.08
3.38
2.94
2.55
*QALMs indicates quality-adjusted life-months; UTI, serious urinary tract infection; and TURP, elective prostatec¬
tomy.
tBaseline values.
The variables to which the model is
most sensitive are the operative mortal¬
ity rate, the utility of the STABLESX
state (both STABLESX and STABp¬
TUR), and the utility of the ASXIMP
state (Fig 1). Figure 1, Top, demon¬
strates the effect of varying the opera¬
tive mortality (at all ages) from half the
baseline assumption to three times the
baseline assumption. This sensitivity
analysis is particularly important both
because the true attributable mortality
of surgery is unclear and because opera¬
tive mortality will vary depending on
both patient factors (eg, comorbidity)
and surgeon/hospital factors (eg, skill or
quality). At threefold operative mortal¬
ity, a threshold favoring watchful wait¬
ing is approached but not reached.
When we used the logistic model for
operative mortality based on deaths at
six weeks (Table 4), the net benefit of
surgery was 3.74 QALMs, approxi¬
mately equivalent to halving the base¬
line rate (Table 6). The relationship of
uSTABLSX and expected quality-ad¬justed survival of the two cohorts is
shown in Fig 1, Center. When the utility
of moderate prostatism, relative to
death (0.0) and the postoperative
asymptomatic state (1.0), is greater
than 0.945, watchful waiting becomes
the preferred strategy. The impact of
varying degrees of disutility associated
with loss of sexual function is seen in Fig
1, Bottom. As the utility of ASXIMP
drops to 0.5, the utilities of the strate¬
gies approach but do not reach a
threshold.
Figure 2 illustrates the interaction of
uSTABLESX, operative mortality, and
the utility assignment for the state of
being impotent without urinary symp¬
toms (uASXIMP). The upper threshold
line, with no disutility assigned to impo¬
tence (uASXIMP = 1.0), is quantita¬
tively the same as for sexually inactive
men who cannot lose utility from impo¬
tence. A man for whom the state of im¬
potence holds considerable disutility(uASXIMP = 0.75 or even 0.50) should
be willing to put up with relatively more
bothersome degrees of symptomatic
prostatism rather than elect surgery.
At high levels of operative mortality,
the absolute thresholds for uSTAB¬
LESX would become relatively low
compared with the thresholds at low
operative mortality. Again, operative
mortality would depend on comorbidity
and the surgeon and hospital selected.
In Fig 3, the net benefit of "operate"
is shown for a spectrum ofstarting ages.
Without utility adjustments, the model
favors "follow" across the age range,
with a net benefit of 0.37 life-months at
age 60 to a net benefit of 2.36 life-
months at age 85. When quality adjust¬
ments are made, however, the net bene¬
fit decreases across this range from 4.68
QALMs at age 60 to -0.11 QALMs (a
slight benefit favoring "follow") at age
85. As one gets older, the initial opera¬
tive toll is steeper, and there are fewer
years of life left to enjoy the symptomat¬
ic benefits of surgery.
Structural Sensitivity Analyses
Several analyses were done to chal¬
lenge the structural assumptions im¬
plicit in the Markov model. We had as¬
sumed watchful waiting would include
regular physician visits and periodic de¬
termination of renal function and resid¬
ual volume to prevent deterioration in
renal function due to obstructive uro-
pathy. But what if some men are lost to
follow-up, or waiting is not as "watch¬
ful" as anticipated? lb evaluate the im¬
portance of this question for the con¬
sequences of the watchful waiting
strategy, we assumed that after five
years, the rate of development of end-
stage renal disease among men with un¬
treated symptomatic prostatism would
be equal to the acute retention rate(.00033 per month) and would be re¬
duced 80% by TURP. Assuming a
monthly excess probability ofdeath due
to end-stage renal disease of .0211 and
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Table 7.—One-Way Sensitivity Analyses—Utilities
Variable Value
1. Quality of life for spontaneous
remission from moderate
prostatism
_
0.90
0.97t
0.99
4.43
2.94
2.51
2 Quality of life for moderate
prostatism
0.85
0.89t
0.93
0.97
5.22
2.94
0.66
-1.61
3. Quality of life for transurethral
resection
0.90
0.82t
0.50
3.01
2.94
2.69
4. Quality of life for serious urinary
tract infection
0.7
0.5t
0
2.93
2.94
2.96
5. Quality of life for severe
incontinence
0.7
0.5t
0
3.05
2.94
2.68
6. Quality of life for severe urinary
symptoms
7. Quality of life for retention and
transurethral resection
0.50
0.25t
0
2.94
2.94
2.95
8. Quality of life for postoperative
impotence without urinary
symptoms
0.50
0.70
0.89t
1.00
1.03
2.01
2.94
3.50
9. Quality of life for mild
Incontinence (wetness) without
other urinary symptoms
0.50
0.89t
0.99
1.40
2.94
3.35
*QALMs indicates quality-adjusted life-months.
tBaseline values.
the utility of a month ofundergoing dial¬
ysis to be 0.80,16 the net benefit favoring
surgery increases only slightly to 3.48
QALMs. Without quality adjustments,
watchful waiting became preferable, as
was the situation in the base-case analy¬
sis, with a net benefit of 0.46 QALMs.
We doubt that the risk of progression to
end-stage renal disease is as great as the
risk of acute retention.
The data from the Maine Prostatecto¬
my Study do not support worse symp¬
tomatic outcomes for individuals with
severe as opposed to moderate symp¬
toms.11 However, an academic concern
might be raised that long-standing ob¬
struction may cause bladder decompen¬
sation (a "cystomyopathy") that could
result in poorer symptomatic outcomes
with delayed compared with immediate
surgery. We had assumed the same re¬
sponse to surgery in "operate" and
"follow." If, however, the chances of
both worse symptoms and unimproved
symptoms after operation were in¬
creased by 25% in "follow," the net ben¬
efit of "operate" would increase slightly
to 3.25 QALMs. If worse or unchanged
postoperative symptomatic outcomes
were 50% more likely after watchful
waiting, the net benefit of "operate"
would become 3.56 QALMs.
COMMENT
Our "base-case" analysis for sexually
active, continent 70-year-old men with
moderate symptomatic prostatism
demonstrates a small improvement in
prognosis of about three QALMs if im¬
mediate transurethral resection is cho¬
sen over watchful waiting. Although
more life-months are lost from opera¬
tive deaths in the "operate" strategy,
the net benefit results from an improve¬
ment in the average mix of symptoms
for the survivors. Prevention ofmorbid¬
ity from UTI or acute retention was a
minimal factor, as was prevention of
mortality due to urosepsis. Again, it
must be emphasized that our model ap¬
plies to men without elevated serum
creatinine levels or large postvoid resid¬
uals, stigmata of chronic retention. We
also assumed waiting was truly watch¬
ful, so that men would not develop pro¬
gressive undetected renal injury due to
obstructive uropathy.
When single variables were analyzed
using sensitivity analysis, the results
were sensitive to the utility assignment
for the STABLESX state, the state that
describes the level of symptoms of the
men who face the decision. The opera¬
tive mortality rate and the utility as¬
signment for lost sexual function also
had appreciable influence but did not in
isolation change the conclusion that "op¬
erate" is the preferred strategy. The
starting age of the cohort also influ¬
enced the result of the model; older indi¬
viduals are at higher surgical risk and
have a shorter life span during which to
reap the benefits of improved urinary
symptoms.
Operative mortality was the single
probability that most influenced the
model. The risk of transurethral sur¬
gery is small and age dependent. The
true attributable risk of surgery will
probably never be known; a randomized
trial of watchful waiting vs immediate
surgery could not define an early differ¬
ence in mortality with a narrow confi¬
dence interval without a prohibitively
large sample size, given the low out¬
come rate (Table 4). If individuals re¬
ferred for surgery have average
comorbidity, comparable with that of
the populations in the Social Security
life tables, then the difference in ob¬
served and expected 12-week mortali¬
ties would be a good estimate for attrib¬
utable risk. However, if healthier
patients undergo operation and sicker
patients are watched, as seems reason¬
able, this calculation would underesti¬
mate attributable mortality. Operative
mortality is also influenced by patient
factors and surgeon/hospital factors.
Patients with comorbid conditions
would be expected to have a higher op¬
erative mortality rate as well as a
shorter expected life span, which would
tend to favor watchful waiting.
The most important result leading to
a better understanding of variation in
prostatectomy rates is the potent influ¬
ence of the utility assignments of
STABLESX and ASXIMP The utility
assignments made by Woodward and
colleagues were not based on prefer¬
ences elicited from patients. Individual
patients would likely assign widely dif¬
ferent utilities to similar symptom
states, depending on the degree to
which these functional states interfered
with their lives and their own psycho¬
logical makeup. The Maine Prostatecto¬
my Study shows that patients with simi¬
lar symptoms can differ markedly in
how much their symptoms bother
them.11 Documented variability in pros¬
tatectomy rates in small geographic ar¬
eas raises questions about whose utili¬
ties influence decisions to operate or
not. Differences in preferences or atti¬
tudes toward risk among the relatively
small number of clinicians who perform
the procedure may be a more likely ex¬
planation for practice variation than
systematic differences among the larg¬
er number of patients who reside in dif¬
ferent areas. Differences in preference
among referring physicians might also
affect utilization rates, as has been do¬
cumented for other procedures.17
Were the utility assignments taken
from Woodward and colleagues12 fair es¬
timates for men with moderate symp¬
tomatic prostatism? One interpretation
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Fig 1.—Expected utility of "operate" (solid line) and "follow" (dashed line) strategies in quality-adjusted life-
months as they vary with three variables to which model is most sensitive: Top, operative mortality rate;
Center, utility assignment for state of moderate symptomatic prostatism (uSTABLSX); and Bottom, utility
assignment for state of impotence without other urinary symptoms (uASXIMP).
of our baseline utility of 0.89 is that
patients in this group would be willing
to risk up to an 11% chance ofdeath to be
relieved of their symptoms. Given that
men in Maine with moderate symptoms,
despite impressive symptom improve¬
ment, had only small, statistically insig¬
nificant improvements in their activity,
mental health, and general health indi¬
ces,11 this utility assignment may well be
too low for most men. Methods for accu¬
rately assessing utilities for health
states relevant to the prostatectomy de¬
cision are an area of current
investigation.18,19
An important implication of the domi¬
nance of these utility factors is that
there can be no truly definitive list of
indications that can be promulgated and
readily reviewed retrospectively to de¬
cide on the appropriateness of a surgical(or nonsurgical) recommendation. Pa¬
tients must be asked about their prefer¬
ences for outcomes, and these will differ
for patients with similar medical histor¬
ies, findings from physical examinations
and laboratory studies, and symptom
levels. For procedures where the "pre¬
ventive" component dominates think¬
ing, such as colectomy for cancer of the
bowel, a uniform threshold for surgery
based on objective criteria that can be
reviewed retrospectively seems feasi¬
ble. However, when operations that
carry risks are undertaken primarily to
improve the quality of life, the threshold
should appropriately vary from patient
to patient, according to the strength of
their feelings about their symptoms and
their attitudes toward risk. Further
study of patient utilities for functional
outcomes following prostatectomy
should help to preserve patient autono¬
my despite the great current pressures
to streamline and standardize medical
practice.20
How "generalizable" is our analysis to
all men undergoing prostatectomy? The
majority ofmen undergo prostatectomy
for symptomatic relief, and we have di¬
rectly modeled the outcomes of immedi¬
ate surgery and watchful waiting for the
group with moderate symptoms. Since
the distribution of symptom states after
surgery seems independent of the initial
symptom state,11 the modeling of the
"operate" strategy should be accurate
for individuals with mild or severe
symptoms, once appropriate utility ad¬justments are made. We doubt that our
results apply to men with evidence of
chronic urinary retention, defined by
postvoid residual urine volumes greater
than 200 mL, evidence of hydroureter
or hydronephrosis, or serum creatinine
levels higher than 180 µ    /L (2
mg/dL). For these men, the "preven¬
tive" argument is stronger. However,
another large group of men who under¬
go prostatectomy are those who have
had an episode of acute urinary reten¬
tion. Some experts have considered
acute retention an absolute indication
for prostatectomy,21 but in actual prac¬
tice patients with episodes of acute ob¬
struction are commonly followed up
rather than operated on. The inability of
prostate size, symptom severity, or
 at Dartmouth College on April 15, 2010 www.jama.comDownloaded from 
 co
_|
m
g
0.96
0.90
-
0.84
0.5 x
Choose: 'Follow'
1.0 x 1.5 x 2.0  2.5  
Operative Mortality (Times Baseline Rate)
uASXIMP =
3.0 x
Fig 2.—Threshold utility of state of moderate symptomatic prostatism (uSTABLSX) as it varies with operative
mortality and with utility assignment for state of impotence without other urinary symptoms (uASXIMP).
s
 >fi.
O
 
e
m
5
 
S 4
 
3
60 65 70 75 80 85
Age, y
Fig 3.—Net benefit of "operate" defined as expected quality-adjusted life-months (QALMs) of "operate"
strategy minus QALMs of "follow" strategy as it varies with patient age.
urodynamic measurements to predict
acute retention has suggested to some
authors that a sudden event such as
prostatic infarction may best explain
acute retention.22,23 If this mechanism is
common, then men who are able to void
successfully after a period of catheter
drainage, after resolution of postinfarct
edema, would seem to be eligible for a
trial of watchful waiting, if there were
no signs of chronic retention. The same
would likely be true for men whose epi¬
sodes of acute retention were precipi¬
tated by bed rest, diuresis, or the use of
anticholinergic medications.
Our decision model has allowed us to
pull together data from many sources to
try to best inform physicians' and pa¬
tients' decisions about prostatectomy.
The Medicare Part A Hospital Claims
database has been particularly helpful
in estimating surgical risks for a very
broad population of men undergoing
TURP. Moreover, the Maine Prostatec¬
tomy Study has provided key informa¬
tion on the functional outcomes of sur¬
gery not available in the urologie
literature. There are still many gaps in
our knowledge, however. The natural
history of untreated prostatism needs
closer definition. Although generous
variation in our natural history assump¬
tions did not substantially influence our
results in isolation, it is possible that a
systematically better or worse natural
history involving many variables might
be important for at least some individ¬
uals whose age, operative risk, or utili¬
ties make the decision more a "toss-up."
We await with interest the results of an
ongoing Veteran's Administration ran-
domized-control trial comparing the re¬
sults of immediate surgery vs watchful
waiting, especially since some men with
acute retention will be included. In the
meantime, however, there is much to do
in developing methods that will allow
clearer communication of currently
available information to patients who
face the prostatectomy decision. The in¬
formed patient who can make quality-
of-life decisions based on his own prefer¬
ences and attitudes toward risk may be
our best safeguard against the concerns
about cost and quality raised by varia¬
tions in medical practices.
APPENDIX: ESTIMATION OF
TRANSITION PROBABILITIES
STABLESX
We calculated the probability of a
spontaneous symptomatic remission by
assuming that 20% of patients not un¬
dergoing operation improve24 and all the
improvement occurs in the first year.22
Therefore, the monthly probability of
remission is .024 for cycles 1 through 12
and .0 thereafter. This assumption is
supported by the short-term remission
rates deserved in the placebo arms of
drug studies.25"28 The monthly probabili¬
ty of symptom deterioration requiring
surgery was .0049 in Ball's natural his¬
tory series; of acute retention, .00033.u
There is no information on the risk of
serious UTI; we assume it is the same as
the acute retention rate. The probabili¬
ty of death depends on age (a function of
the number of elapsed Markov cycles)
and is taken from gender-specific US
life tables built into the model.29 We use
the same monthly probability ofdeath in
all nonsurgical states except UTI.
ASX
After spontaneous remission of
symptoms, deterioration can occur; the
remissions in the series of Ball et al24 and
Birkoff et al22 seemed durable, but fol¬
low-up was only three to five years. In
the series of Craigen et al,30 ten opera¬
tions were performed in 2496 person-
months beyond three years of follow-up;
although these individuals may not have
been asymptomatic, we use these data
to calculate a "worst case" relapse rate
of 0.004 per month. We also conserva¬
tively assume that the risk of retention
and infection does not decrease with
symptomatic remission, which is gener¬
ally not accompanied by "urodynamic"
UTI
The risk of death from serious UTI is
estimated to be
.0332; survivors go on to
elective TURP (UTITURP).
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TURP (UTITURP, RETTURP)
Operative mortality is age dependent
and may be underestimated when in¬
hospital or 30-day mortality is exam¬
ined.5,33 Our operative mortality esti¬
mates were derived from Medicare
claims data (Table 4); the logistic func¬
tion itself was built into the model. The
12-week data were used in the base
case. We assumed the probability of re¬
vision TURP soon after operation
would be .015.34,35 For survivors not re¬
quiring reoperation, probabilities for
symptom transitions from the Maine
Prostatectomy Study were as follows:
6% worse, which we broke down to a
.055 probability of transition to
WORSpTUR and a .005 probability of
severe incontinence34,36; 18% the same(STABpTUR); and 77% better (ASXp-
TUR). In the base case, transitions
were the same for surgery following
treated UTI or acute retention.
For men who go to each of the three
symptom states (ASXpTUR, STABp-
TUR, WORSpTUR), the probability of
also having minor wetness or impotence
is .04 and
.05, respectively. These fig¬
ures represent the probability that men
continent or sexually active at the out¬
set of the Maine Prostatectomy Study
would report wetness or inability to get
an erection at 3, 6, and 12 months after
surgery.
ASXpTUR (ASXIMP, ASXWET)
We calculate a monthly probability of
revision of .0018 (for both stricture re¬
quiring more than in-office dilatation
and the occurrence of benign prostatic
hypertrophy).36 This estimate yields cu¬
mulative reoperation frequencies (Ta-
ble 5) similar to those documented in
reviewing Medicare claims data.5 We
assume that surgery reduces the risk of
infection and retention by 80% to .00007
per month.
STABpTUR (STABIMP, STABWET)
We assume revision and complication
probabilities in this state are the same
as in ASXpTUR.
WORSpTUR (WORSIMP,
WORSWET), INCONT, DEAD
No transitions are allowed from these
first four states except with death; the
dead state is an "absorbing" state with
no transitions.
This study was supported by grants from the
John A. Hartford Foundation Ine and the National
Center for Health Services Research.
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